Stock Ratings / Health Care / BJDX / forecast

IVF (43) NXGL (32) ICCM (46) CODX (37) ⌘ Pro Terminal →

Bluejay Diagnostics Inc. (BJDX) 12-Month Stock Forecast & Price Target Cone

Q: What is BJDX's 12-month stock price target?

Bluejay Diagnostics Inc. (BJDX) carries a 12-month consensus base price target of $0.51 (-5.6% from $0.54), with a bull-case target of $8.34 and a bear-case floor of $0.4.

Q: Is BJDX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates BJDX D (Sell — SELL) with an RQD Confidence score of 45/100.

$0.54 -5.08% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.53

Bluejay Diagnostics Inc. (BJDX) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $2.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.53 (-1.10%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BJDX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY BJDX SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$0.82-8.5% Next Q

Q2 (-2Q)

Grade C-$0.75-22.7% Next Q

Q3 (-1Q)

Grade D$0.58-6.9% Next Q

Current

Grade D$0.54-6.3% Hist 90D α

Trajectory: C- (53) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BJDX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BJDX currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.82) and Max Pain ($0.57) forces dealer call-delta covering toward $8.34.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BJDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BJDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your BJDX Position Size: $10,000

Shares at $0.54: 18518.5 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.40

$7,407

$-2,593 (-25.9%)

12M Consensus BaseTarget $0.51

$9,444

$-556 (-5.6%)

12M Bull Case BreakoutTarget $8.34

$154,444

+$144,444 (+1444.4%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$8	69%	B
JP MorganUS Large-Cap Research	SELL	$0	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BJDX)

✓Walkthrough of BJDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BJDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -70.17%▲ RESISTANCE BREAKOUT

2026-10-30O $0.53H $0.60L $0.46C $0.54VOL 280.9K

RES: $0.47SUP: $-0.26SMA50: $0.82SMA200: $1.85

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BJDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BJDX Butterfly Map → + Track BJDX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BJDX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BJDX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BJDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BJDX)

Health Care Rank #493 of 1016 ⚔️ IVF vs BJDX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BJDX vs. IVF, NXGL, ICCM, CODX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bluejay Diagnostics Inc. (BJDX) ranks #493 by composite RQD confidence (45/100, grade D) and #990 by equity capitalization ($2.4M). Within this direct 5-issuer industry benchmark cohort, BJDX leads on earnings valuation at N/A trailing P/E, while BJDX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ICCM currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with BJDX at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BJDX ACTIVE Bluejay Diagnostics Inc.	D	45/100	—	—	-35.0%	-5.08%	$2.4M	Benchmark Subject
IVF INVO Fertility Inc.	D-	43/100	—	96.0%	-35.0%	-3.60%	$2.5M	/ivf-vs-bjdx →
NXGL NexGel Inc	E	32/100	—	39.5%	-35.0%	-3.72%	$1.9M	/nxgl-vs-bjdx →
ICCM IceCure Medical Ltd.	D	46/100	—	36.3%	-35.0%	-2.13%	$3.3M	/iccm-vs-bjdx →
CODX Co-Diagnostics Inc.	D-	37/100	—	64.3%	-35.0%	-10.49%	$3.5M	/codx-vs-bjdx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001704287

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bluejay Diagnostics Inc. (BJDX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$6.8M, operating cash flow of -$6.1M, and free cash flow of -$6.2M (+23.4% YoY). On the balance sheet, BJDX closed FY2025 with $7.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$6.8M	-$6.1M	-$6.2M	$7.1M	—
FY2024 (FY)	2024-12-31	$0	-$7.7M	-$7.8M	-$8.1M	$6.7M	—
FY2023 (FY)	2023-12-31	$0	-$10.0M	-$8.3M	-$8.3M	—	—

3. BJDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BJDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Bluejay Diagnostics Inc. (NASDAQ: BJDX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.54 (-5.08% 1D, market cap $2.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BJDX ranks #493 in composite RQD confidence.

How does BJDX compare to IVF and NXGL in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), BJDX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IVF (INVO Fertility Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M) and NXGL (NexGel Inc) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $1.9M). Among the 5-stock peer group, BJDX leads on earnings multiple (N/A) while BJDX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BJDX?

Per BJDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001704287), Bluejay Diagnostics Inc. generated $0 in revenue, -$6.8M in net income, and -$6.2M in free cash flow against $7.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BJDX trading relative to its 50-day, 200-day, and 52-week technical levels?

BJDX last traded at $0.54 (-5.08% on volume of 98,288 shares), positioning the stock -34.15% below its 50-day simple moving average ($0.82) and -70.81% below its 200-day simple moving average ($1.85). Across its 52-week range of $0.46 to $7.94, BJDX sits at the 1.1% percentile with a 14-day RSI of 29.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.61).

BJDX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is BJDX's 12-month stock price target?

Bluejay Diagnostics Inc. (BJDX) carries a 12-month consensus base price target of $0.51 (-5.6% from $0.54), with a bull-case target of $8.34 and a bear-case floor of $0.4.

Is BJDX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates BJDX D (Sell — SELL) with an RQD Confidence score of 45/100.

Direct Sub-Reports: BJDX RQD Cockpit BJDX 12M Forecast BJDX Earnings & Move BJDX Dividends & DRIP BJDX Insiders & 13F BJDX Whale Options BJDX Profit Sankey BJDX News & Why